J.P. Morgan Healthcare Conference Closes With One Medtech Megadeal and Cautious Optimism

The 44th J.P. Morgan Healthcare Conference ended in San Francisco this week with medical technology providing the week's megadeal and investors in a cautiously hopeful mood, according to early assessments from analysts and attendees.

PitchBook analysts Brian Wright and Ben Zercher described the overall tone of the January 12-15 meeting as understated, cautious optimism after a tumultuous policy year in 2025, in a note published Friday.

Medtech supplies the megadeal

Boston Scientific's agreement to buy Penumbra for $14.5 billion in cash and stock was one of the most significant announcements of the week, the analysts wrote. They put the price at an estimated 11.3 times revenue and a 19% premium to Penumbra's share price before the announcement, and called it Boston Scientific's largest acquisition since its $27 billion purchase of Guidant in 2006. The company had also announced a deal for Valencia Technologies earlier in the week.

The note said medtech deal volume stayed in line with 2024's muted levels while large transactions pushed total deal value to multiyear highs, and that PitchBook expects heightened medtech M&A in 2026. Biopharma dealmaking was comparatively quiet, with several rumored acquisitions failing to materialize.

Medical Device Network also noted a lull in M&A announcements across medtech and pharma at this year's event, with the Penumbra deal the exception.

Regulators court the industry

FDA Commissioner Marty Makary told attendees the agency was taking a more access- and execution-oriented posture, according to PitchBook. He described a shift toward accepting one pivotal trial in certain settings and highlighted new approach methods, including lab-on-chip systems and AI-enabled models, that could reduce reliance on animal studies. Former FDA drug center head Richard Pazdur, speaking on a panel hosted by STAT News, described haphazard change management at the agency, the note said.

CMS Administrator Mehmet Oz and senior CMS officials used the conference for industry outreach, the analysts wrote, with themes including quality and access, interoperability and data access, price transparency and easing prior authorization.

Artificial intelligence was another recurring theme. PitchBook said the discussion across biopharma and health technology shifted from AI's theoretical promise to demonstrated operational returns, with standing-room-only sessions for ambient clinical documentation companies.

Questions about the format

Not every attendee was convinced the meeting still pays off. Dave Rosa, chief executive of neurology device company NeuroOne, who has attended for about 25 years, told Medical Device Network that the conference's perceived value is declining.

Rosa said his room cost almost $2,500 a night and that half-hour meetings leave little room for substantive discussion. "My point is that people's feeling that they're not getting as much quality from attending the meeting, coupled with the astronomical, out of control costs, are dampening the overall enthusiasm to attend," he said.